Inari Medical Reports Q3 Loss, Higher Revenue; 2024 Sales Midpoint Guidance Boosted; Shares Rise

MT Newswires Live

Oct 29, 2024

Inari Medical (NARI) reported a Q3 net loss late Monday of $0.31 per diluted share, compared with net income of $0.05 a year earlier.

Analysts polled by Capital IQ expected a $0.18 loss.

Revenue in the three months ended Sept. 30 rose to $153.4 million from $126.4 million a year earlier.

Analysts surveyed by Capital IQ expected $150.7 million.

In 2024, the medical device company expects revenue of $601.5 million to $604.5 million versus the previous outlook of $594.5 million to $604.5 million.

Analysts project $600 million.

Inari said it continues to expect to reach sustained operating profitability in H1.

The company's shares rose 10% in after-hours activity.

Price: 47.00, Change: +4.44, Percent Change: +10.43

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2479465147"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479465147\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2479465147?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-29 05:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479465147","market":"sh","top_or_hot":-1,"title":"Inari Medical Reports Q3 Loss, Higher Revenue; 2024 Sales Midpoint Guidance Boosted; Shares Rise","media":"MT Newswires Live","content":"<html><body><p> Inari Medical (NARI) reported a Q3 net loss late Monday of $0.31 per diluted share, compared with net income of $0.05 a year earlier.</p><p>Analysts polled by Capital IQ expected a $0.18 loss.</p><p>Revenue in the three months ended Sept. 30 rose to $153.4 million from $126.4 million a year earlier.</p><p>Analysts surveyed by Capital IQ expected $150.7 million.</p><p>In 2024, the medical device company expects revenue of $601.5 million to $604.5 million versus the previous outlook of $594.5 million to $604.5 million.</p><p>Analysts project $600 million.</p><p>Inari said it continues to expect to reach sustained operating profitability in H1.</p><p>The company's shares rose 10% in after-hours activity.</p><p>Price: 47.00, Change: +4.44, Percent Change: +10.43</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inari Medical Reports Q3 Loss, Higher Revenue; 2024 Sales Midpoint Guidance Boosted; Shares Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInari Medical Reports Q3 Loss, Higher Revenue; 2024 Sales Midpoint Guidance Boosted; Shares Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-29 05:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Inari Medical (NARI) reported a Q3 net loss late Monday of $0.31 per diluted share, compared with net income of $0.05 a year earlier.</p><p>Analysts polled by Capital IQ expected a $0.18 loss.</p><p>Revenue in the three months ended Sept. 30 rose to $153.4 million from $126.4 million a year earlier.</p><p>Analysts surveyed by Capital IQ expected $150.7 million.</p><p>In 2024, the medical device company expects revenue of $601.5 million to $604.5 million versus the previous outlook of $594.5 million to $604.5 million.</p><p>Analysts project $600 million.</p><p>Inari said it continues to expect to reach sustained operating profitability in H1.</p><p>The company's shares rose 10% in after-hours activity.</p><p>Price: 47.00, Change: +4.44, Percent Change: +10.43</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NARI","symbol_name":"Inari Medical, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2479465147","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479465147","pubTimestamp":1730151709,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Inari Medical  reported a Q3 net loss late Monday of $0.31 per diluted share, compared with net income of $0.05 a year earlier.Analysts polled by Capital IQ expected a $0.18 loss.Revenue in the three months ended Sept. 30 rose to $153.4 million from $126.4 million a year earlier.Analysts surveyed by Capital IQ expected $150.7 million.In 2024, the medical device company expects revenue of $601.5 million to $604.5 million versus the previous outlook of $594.5 million to $604.5 million.Analysts project $600 million.Inari said it continues to expect to reach sustained operating profitability in H1.The company's shares rose 10% in after-hours activity.Price: 47.00, Change: +4.44, Percent Change: +10.43","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NARI":"Inari Medical, Inc."},"translate_title":"伊那里医疗报告第三季度亏损，收入增加；2024年销售中点指引上调；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NARI":1},"content_text":"Inari Medical (NARI) reported a Q3 net loss late Monday of $0.31 per diluted share, compared with net income of $0.05 a year earlier.Analysts polled by Capital IQ expected a $0.18 loss.Revenue in the three months ended Sept. 30 rose to $153.4 million from $126.4 million a year earlier.Analysts surveyed by Capital IQ expected $150.7 million.In 2024, the medical device company expects revenue of $601.5 million to $604.5 million versus the previous outlook of $594.5 million to $604.5 million.Analysts project $600 million.Inari said it continues to expect to reach sustained operating profitability in H1.The company's shares rose 10% in after-hours activity.Price: 47.00, Change: +4.44, Percent Change: +10.43","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}